Treatment Goals, Side Effects, and Supportive Care Strategies for Patients and Caregivers with HER2+ BC
Experts discuss how, discuss patient experiences with an oral chemotherapy regimen, highlighting benefits like treatment autonomy, challenges such as pill burden and gastrointestinal toxicities, and the importance of proactive side effect management and patient education.
Video content above is prompted by the following:
- What has been your experience with oral regimens and managing toxicities and getting women acclimated to it?
Recent Videos
Related Content
FDA Approves T-DXd for Previously Treated HER2-Low and -Ultralow Metastatic Breast Cancer
Published: January 27th 2025 | Updated: January 28th 2025Article
T-DXd has received FDA approval for the treatment of unresectable or metastatic HR+, HER2-low/-ultralow breast cancer in patients whose disease progressed on prior endocrine therapy in the metastatic setting.
